Cancer is one of the most common causes of death worldwide. Lung cancer is the leading cause of cancer-related death worldwide [1], with a five-year survival rate of 10% in Europe and 15% in the United States [2,3]. Strikingly, for lung cancers detected in their early stage, the rate of recurrence within five years is less than 50%. When detected early, current therapies often cure common cancers, including those of the lung, breast, colon, rectum, stomach, and prostate [4]. Therefore, the development of reliable, noninvasive, and cost-effective early detection methods for common cancers is a priority of translational cancer research. Theoretically, a single method that detects multiple common cancer types at an early stage would have the biggest payoff for cancer control. In a new study published in *PLoS Medicine*, Shames et al. aim for a big payoff by searching genome-wide for CpG island methylation markers characteristic of not just one type of cancer, but common to several cancers of epithelial origin [16]. Identification of such markers could facilitate detection and diagnosis, and might also shed light on molecular pathways that are characteristic of tumorigenesis in general, potentially providing new clinically relevant therapeutic targets with more widespread application.

The subset of CpG islands subjected to aberrant methylation in primary human tumors is non-random, due in part to selection of gene silencing events that favor unregulated cell growth, and also due to intrinsic sequence properties that may underlie gene-specific susceptibility to methylation [7–10]. One hypothesis is that alterations in DNA methylation play a key role in tumor initiation, and if this is true, methylation markers are ideally suited for detecting cancer in the early stages [11,12]. In contrast to tumor type–specific methylation markers, pan-cancer methylation markers could detect a far greater number of early stage cancers. Initial results of a prospective study of such markers are encouraging [13]. Belinsky and colleagues used aberrant methylation in a six-gene panel to detect lung cancer in sputum samples taken months to years prior to the clinical onset of cancer [13]. Other bodily fluids are similarly useful for detection of noninvasive cancer via methylation markers, such as urine for kidney, bladder, or prostate cancer, and serum or nipple aspirates for breast cancer [14,15]. Notably, the panels of aberrantly methylated genes in these different tumor types overlap significantly, indicating that assays for pan-cancer methylation markers are already available for testing. The important role of aberrant methylation in cancer detection and prognostication has been established on a small proportion of the CpG island–containing genes. Thus, there remains a potentially vast, untapped resource for cancer-specific methylation biomarkers.

**A New Study of Pan-Cancer Methylation Markers**

In a new study published in *PLoS Medicine*, Shames et al. aim for a big payoff by searching genome-wide for CpG island methylation markers characteristic of not just one type of cancer, but common to several cancers of epithelial origin [16]. Identification of such markers could facilitate detection and diagnosis, and might also shed light on molecular pathways that are characteristic of tumorigenesis in general, potentially providing new clinically relevant therapeutic targets with more widespread application.

The subset of CpG islands subjected to aberrant methylation in primary human tumors is non-random, due in part to selection of gene silencing events that favor unregulated cell growth, and also due to intrinsic sequence properties that may underlie gene-specific susceptibility to methylation [7–10]. One hypothesis is that alterations in DNA methylation play a key role in tumor initiation, and if this is true, methylation markers are ideally suited for detecting cancer in the early stages [11,12]. In contrast to tumor type–specific methylation markers, pan-cancer methylation markers could detect a far greater number of early stage cancers. Initial results of a prospective study of such markers are encouraging [13]. Belinsky and colleagues used aberrant methylation in a six-gene panel to detect lung cancer in sputum samples taken months to years prior to the clinical onset of cancer [13]. Other bodily fluids are similarly useful for detection of noninvasive cancer via methylation markers, such as urine for kidney, bladder, or prostate cancer, and serum or nipple aspirates for breast cancer [14,15]. Notably, the panels of aberrantly methylated genes in these different tumor types overlap significantly, indicating that assays for pan-cancer methylation markers are already available for testing. The important role of aberrant methylation in cancer detection and prognostication has been established on a small proportion of the CpG island–containing genes. Thus, there remains a potentially vast, untapped resource for cancer-specific methylation biomarkers.

The Perspectives section is for experts to discuss the clinical practice or public health implications of a published article that is freely available online.

*To whom correspondence should be addressed.
E-mail: jcostello@cc.ucsf.edu

**Funding:** The authors have received funding from the Leukemia and Lymphoma Society of America (CP), the National Institutes of Health (CP, JFC), the National Lung Cancer Partnership (RMB, CP), and the American Cancer Society (JFC).

**Competing Interests:** CP is a consultant for Epigenomics and Quest Diagnostics.

**Citation:** Brena RM, Plass C, Costello JF (2006) Mining methylation for early detection of common cancers. *PLoS Med* 3(12): e479. doi:10.1371/journal.pmed.0030479

**Copyright:** © 2006 Brena et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Romulo M. Brena is in the Department of Molecular Genetics and the Department of Molecular Virology, Immunology, and Medical Genetics at The Ohio State University, Columbus, Ohio, United States of America. Christoph Plass is in the Department of Molecular Virology, Immunology, and Medical Genetics, Division of Human Cancer Genetics, College of Medicine and Public Health, and the Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio, United States of America. Joseph F. Costello is in the Department of Neurological Surgery, University of California San Francisco Comprehensive Cancer Center, San Francisco, California, United States of America.

*To whom correspondence should be addressed.
E-mail: jcostello@cc.ucsf.edu
Shames and colleagues began the quest for a pan-cancer marker by gene expression profiling of non-small cell lung cancer cell lines before and after treatment with the DNA methylation inhibitor 5-aza-2’-deoxycytidine. Their initial goal was to find genes expressed in a normal cell from which the tumor might arise, namely human bronchial epithelial cells, but silenced in the cancer cell lines and reactivated by inhibition of DNA methylation. The initial experiment netted 132 tumor-specific candidates. Winnowing this gene subset to a manageable 45 genes involved random selection, and was followed by validation of gene silencing in primary lung tumors relative to the tumor-free adjacent lung.

The eight most frequently methylated genes obtained from the lung cancer data were then tested in a set of 109 tumors from breast, colon, and prostate. Four genes, BCNI, MSXI, CCNA1, and ALDHL1A3, showed extensive DNA methylation in all four epithelial cancers. In particular, BCNI and MSXI were highly sensitive and specific for tumor detection.

The authors concluded that key pathways altered epigenetically in the tumorigenic process may be shared across cancers of epithelial cell origin, despite obvious differences in their tissue source. This finding is of importance, since it highlights the possibility of identifying a common epigenetic denominator acting across tumor types, and perhaps underlying malignant transformation in general.

However, we must again consider that these genes may be susceptible to aberrant DNA methylation, which could be due in part to their primary DNA sequence. Thus, it remains to be determined if the high frequency of DNA methylation observed in the BCNI, MSXI, CCNA1, and ALDHL1A3 genes stems from a functional need to abrogate expression and thus contribute to tumor initiation and, or progression, from an intrinsic susceptibility of these loci to aberrant DNA methylation, or both. In either case, their utility as markers of cancer cells will be unaffected.

Cautions and Clinical Implications

One hazard of using DNA methylation as a marker of cancer is the distinct possibility of false positives. The perfect marker would detect all cancer cases (100% sensitivity) and would not mistake normal cells for cancer cells (100% specificity). However, the influence of ageing, diet, or hormones on DNA methylation may confound results if even a minor fraction of normal cells are methylated at the gene of interest in cancer-free individuals. This cautionary note has been sounded by Shames and colleagues [16] and by others [17]. The problem is that an assay sufficiently sensitive to detect a rare cancer cell in blood or bodily fluids could be particularly susceptible to this pitfall. Nevertheless, developing a single routine test for major cancer types in at-risk or asymptomatic individuals, paired with follow-up tests for specific malignancies, is a goal of high priority.

Efforts toward the perfect universal DNA methylation marker for early detection of tumors are well underway in research laboratories worldwide. Epigenetics researchers from Asia, Europe, and the US are joining forces to map the entire epigenome of normal and cancer cells [18]. Assays are currently available to detect aberrant DNA methylation in samples such as sputum, blood, feces, urine, and nipple aspirates, which can be procured via minimally invasive procedures and are likely to contain tumor cells and tumor DNA shed from a primary tumor mass [14,15].

Research endeavors such as those of Shames et al. are pivotal for the first phase of identification of suitable markers. Technological advances, such as the development of DNA methylation arrays, will undoubtedly aid in the methylation marker discovery phase. The next phase will include testing markers retrospectively and then prospectively in clinical settings, in a high-throughput and cost-effective manner. Coupling the discovery of new DNA methylation markers with investigation into their functional relevance will benefit early detection efforts and improve our understanding of the tumorigenic process.

Currently recommended methods for early detection of cancer include spiral computed tomography for patients at risk for lung cancer, breast exams and mammography for breast cancer detection, fecal occult blood tests and colonoscopy for colon cancer, and endoscopy for gastric cancers. However, several of these methods are expensive, prohibiting large-scale population-based use. It remains to be seen whether the new suite of DNA methylation markers from Shames et al. or those from prior studies will be true pan-cancer markers, and most importantly, whether they will outperform existing methods for early detection.

References

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, et al. (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10–30.
2. Jemal A, Clegg LX, Ward E, Ries LA, Xu X, et al. (2004) Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 101: 3–27.
3. Belinsky SA (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4: 215–228.
4. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153–156.
5. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415–428.
6. Hoffmann MJ, Schulz WA (2005) Causes and consequences of DNA hypomethylation in human cancer. Biochim Biophys Acta 1725: 296–321.
7. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, et al. (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24: 152–158.
8. Feltus FA, Lee EK, Costello JF, Plass C, Veriño PM (2003) Predicting aberrant CpG island methylation. Proc Natl Acad Sci U S A 100: 12253–12258.
9. Feltus FA, Lee EK, Costello JF, Plass C, Veriño PM (2006) DNA motifs associated with aberrant CpG island methylation. Genomics 87: 572–579.
10. Das R, Dimitrova N, Xuaz Z, Rollins RA, Haghhighi F, et al. (2006) Computational prediction of methylation status in human genomic sequences. Proc Natl Acad Sci U S A 103: 10713–10716.
11. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, et al. (2003) Induction of tumors in mice by genomic hypomethylation. Science 300: 489–492.
12. Laird PW (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253–266.
13. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, et al. (2001) Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 66: 5358–5344.
14. Cains P, Esteller M, Herman JG, Scherberg M, Jeronimo C, et al. (2001) Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 7: 2727–2730.
15. Kressestein R, Rauter E, Duldani E, Bhatagi C, Elha H, et al. (2004) Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 10: 28–32.
16. Shames DS, Giraud L, Gao B, Sato M, Lewis CM, et al. (2006) A genome-wide screen for hypermethylated genes in lung cancer identifies tumor-specific methylation markers for multiple malignancies. PLoS Med 3: e486. doi:10.1371/journal.pmed.0040486
17. Suzuki K, Suzuki I, Leodolter A, Alonso S, Horuchi S, et al. (2006) Global DNA methylation in gastrointestinal cancer is age dependent and preceding genomic damage. Cancer Cell 9: 199–207.
18. Qiu J (2006) Epigenetics: Unfinished symphony. Nature 441: 145–145.